Recreation management : A framework for the effective management of community recreation facilities

by Torkildsen, G.
Published 1987

Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model

by Torkildsen G, Narvekar A, Bergmann M
Published 2015-09-01

Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects

by Malhotra RP, Meier E, Torkildsen G, Gomes PJ, Jasek MC
Published 2019-02-01

Safety and comfort evaluation of a new formulation of Visine® lubricant eye drops containing HydroBlend™ and GentlePur™

by Torkildsen G, Frisch S, Bai M, Gentner III L, Doshi U, Zhang J
Published 2016-02-01

Ocular iontophoresis of EGP-437 (dexamethasone phosphate) in dry eye patients: results of a randomized clinical trial

by Patane MA, Cohen A, From S, Torkildsen G, Welch D, Ousler GW 3rd
Published 2011-05-01

Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis

by McLaurin E, Bergmann M, Narvekar A, Adewale A, Gomes P, Torkildsen G
Published 2017-06-01

Safety and efficacy of MIM D3 ophthalmic solutions in a randomized placebo controlled Phase 2 clinical trial in patients with dry eye

by Meerovitch K, Torkildsen G, Lonsdale J, Goldfarb H, Lama T, Cumberlidge G, Ousler GW III
Published 2013-06-01

Evaluation of a new artificial tear formulation for the management of tear film stability and visual function in patients with dry eye

by Torkildsen G, Brujic M, Cooper MS, Karpecki P, Majmudar P, Trattler W, Reis M, Ciolino JB
Published 2017-10-01

A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease

by Taylor M, Ousler G, Torkildsen G, Walshe C, Fyfe MCT, Rowley A, Webber S, Sheppard JD, Duggal A
Published 2019-02-01